• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.神经内分泌癌患者的(68)Ga-DOTATOC PET与基因表达谱:PET示踪剂摄取与生长抑素受体2型基因表达之间的强相关性
Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):59-72. eCollection 2016.
2
68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.68Ga-DOTATOC与FDG对临床前神经母细胞瘤模型的PET成像
Anticancer Res. 2016 Sep;36(9):4459-66. doi: 10.21873/anticanres.10990.
3
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.肺神经内分泌肿瘤 somatostatin 受体 PET/CT 成像特征与免疫组化的相关性:一项回顾性观察研究。
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4182-4193. doi: 10.1007/s00259-022-05848-z. Epub 2022 Jun 8.
4
Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy.前瞻性患者内评估未标记的奥曲肽预给药对神经内分泌肿瘤患者动态全身PET评估的镓[68Ga] DOTATOC生物分布和肿瘤摄取的影响:对诊断和治疗的意义
Mol Imaging Biol. 2021 Oct;23(5):766-774. doi: 10.1007/s11307-021-01600-5. Epub 2021 Apr 7.
5
Heterogeneity of SSTR2 Expression Assessed by Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors.应用 Ga-DOTATOC PET/CT 测量变异系数评估神经内分泌肿瘤患者中 SSTR2 的异质性。
J Nucl Med. 2022 Oct;63(10):1509-1514. doi: 10.2967/jnumed.121.262928. Epub 2022 Mar 10.
6
Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.生长抑素受体2免疫组织病理学表达与68Ga-DOTATOC PET/CT标准化摄取值的相关性
Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):48-52. doi: 10.1007/s00259-008-0944-5. Epub 2008 Sep 20.
7
Clinical significance of atypical Ga-DOTATOC prostatic uptake on PET/CT: A ten-year review.PET/CT上非典型镓-奥曲肽前列腺摄取的临床意义:十年回顾
Hell J Nucl Med. 2023 May-Aug;26(2):94-98. doi: 10.1967/s002449912571. Epub 2023 Aug 4.
8
Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.用于生长抑素受体2靶向治疗的实验性BT4C胶质瘤模型的可行性
Acta Oncol. 2014 Aug;53(8):1125-34. doi: 10.3109/0284186X.2014.925577. Epub 2014 Jun 24.
9
Lower Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study.功能性垂体神经内分泌肿瘤与正常垂体腺相比,镓-DOTATOC 摄取较低——一项概念验证研究。
Clin Endocrinol (Oxf). 2020 Mar;92(3):222-231. doi: 10.1111/cen.14144. Epub 2020 Jan 9.
10
Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy.高级别胶质瘤中的生长抑素受体2型:使用(68)Ga-DOTA肽的PET/CT、与预后标志物的相关性以及对靶向放疗的意义
EJNMMI Res. 2015 Apr 22;5:25. doi: 10.1186/s13550-015-0106-2. eCollection 2015.

引用本文的文献

1
Prediction of Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on Ga-DOTATATE PET/CT.利用镓 [68Ga] DOTATATE PET/CT 上的半自动肿瘤勾画预测神经内分泌肿瘤患者的镥 [177Lu] DOTATATE 治疗结果
Cancers (Basel). 2023 Dec 31;16(1):200. doi: 10.3390/cancers16010200.
2
Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.胃肠胰神经内分泌肿瘤的诊断管理:放射科医师的技术优化及技巧。
Tomography. 2023 Jan 27;9(1):217-246. doi: 10.3390/tomography9010018.
3
PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.临床成人肿瘤学中的PET-CT - VI. 原发性皮肤癌、肉瘤和神经内分泌肿瘤。
Cancers (Basel). 2022 Jun 8;14(12):2835. doi: 10.3390/cancers14122835.
4
Prospective Phase II Trial of Prognostication by Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy.神经内分泌肿瘤患者 Ga-NOTA-AE105 uPAR PET 预后预测的前瞻性 II 期试验:对 uPAR 靶向治疗的影响。
J Nucl Med. 2022 Sep;63(9):1371-1377. doi: 10.2967/jnumed.121.263177. Epub 2022 Jan 20.
5
Correlation of Somatostatin Receptor 1-5 Expression, [Ga]Ga-DOTANOC, [F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms.前瞻性胰腺神经内分泌肿瘤队列中生长抑素受体1 - 5表达、[镓]镓 - DOTANOC、[氟]氟 - FDG PET/CT与临床结局的相关性
Cancers (Basel). 2021 Dec 29;14(1):162. doi: 10.3390/cancers14010162.
6
Somatostatin and Its Receptor System in Colorectal Cancer.结直肠癌中的生长抑素及其受体系统
Biomedicines. 2021 Nov 22;9(11):1743. doi: 10.3390/biomedicines9111743.
7
Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.前瞻性研究在分化良好的神经内分泌肿瘤患者中进行动态全身 68Ga-DOTATOC-PET/CT 采集。
Sci Rep. 2021 Mar 1;11(1):4727. doi: 10.1038/s41598-021-83965-9.
8
Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.神经内分泌肿瘤的分子成像与放射性核素治疗进展
J Clin Med. 2020 Nov 16;9(11):3679. doi: 10.3390/jcm9113679.
9
Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.用于乳腺癌和神经内分泌肿瘤的放射性药物:组织特征如何影响治疗选择的两个实例。
Cancers (Basel). 2020 Mar 25;12(4):781. doi: 10.3390/cancers12040781.
10
Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.铜- DOTATATE PET/CT 与神经内分泌肿瘤患者总生存和无进展生存的预测。
J Nucl Med. 2020 Oct;61(10):1491-1497. doi: 10.2967/jnumed.119.240143. Epub 2020 Feb 28.

本文引用的文献

1
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.胃肠胰神经内分泌癌:全面综述。
Diagnostics (Basel). 2015 Apr 8;5(2):119-76. doi: 10.3390/diagnostics5020119.
2
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.首例人体uPAR正电子发射断层显像:癌症侵袭性成像
Theranostics. 2015 Sep 13;5(12):1303-16. doi: 10.7150/thno.12956. eCollection 2015.
3
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.尿激酶型纤溶酶原激活物受体作为胶质母细胞瘤潜在的正电子发射断层显像生物标志物
J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.
4
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.放射性物质在神经内分泌肿瘤诊断和治疗中的应用。
Scand J Gastroenterol. 2015 Jun;50(6):740-7. doi: 10.3109/00365521.2015.1033454.
5
64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.64Cu-DOTATATE正电子发射断层显像术用于神经内分泌肿瘤:112例患者中与111In-DTPA-奥曲肽的前瞻性直接比较
J Nucl Med. 2015 Jun;56(6):847-54. doi: 10.2967/jnumed.115.156539. Epub 2015 May 7.
6
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.用于神经内分泌肿瘤生长抑素受体成像的正电子发射断层显像(PET)示踪剂:现状及文献综述
Future Oncol. 2014 Nov;10(14):2259-77. doi: 10.2217/fon.14.139.
7
Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment.胃肠道神经内分泌肿瘤的特征:对治疗的意义
Endocr Relat Cancer. 2014;21(6):R445-60. doi: 10.1530/ERC-14-0106.
8
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.2014年北欧胃肠胰神经内分泌肿瘤诊断与治疗指南。
Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20.
9
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.兰瑞肽治疗转移性胃肠胰神经内分泌肿瘤。
N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.
10
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).尿激酶型纤溶酶原激活物受体(uPAR)和纤溶酶原激活物抑制剂-1(PAI-1)是早期口腔鳞状细胞癌(OSCC)潜在的预测生物标志物。
PLoS One. 2014 Jul 7;9(7):e101895. doi: 10.1371/journal.pone.0101895. eCollection 2014.

神经内分泌癌患者的(68)Ga-DOTATOC PET与基因表达谱:PET示踪剂摄取与生长抑素受体2型基因表达之间的强相关性

(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

作者信息

Olsen Ingrid H, Langer Seppo W, Federspiel Birgitte H, Oxbøl Jytte, Loft Annika, Berthelsen Anne Kiil, Mortensen Jann, Oturai Peter, Knigge Ulrich, Kjær Andreas

机构信息

European NET Centre of Excellence, Rigshospitalet, University of CopenhagenDenmark; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of CopenhagenDenmark; Department of Endocrinology, Rigshospitalet, University of CopenhagenDenmark; Department of Surgical Gastroenterology, Rigshospitalet, University of CopenhagenDenmark; Department of Oncology, Rigshospitalet, University of CopenhagenDenmark; Department of Pathology, Rigshospitalet, University of CopenhagenDenmark.

European NET Centre of Excellence, Rigshospitalet, University of CopenhagenDenmark; Department of Oncology, Rigshospitalet, University of CopenhagenDenmark.

出版信息

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):59-72. eCollection 2016.

PMID:27069766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4749505/
Abstract

Somatostatin receptor expression on both protein and gene expression level was compared with in vivo (68)Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC). Twenty-one patients with verified NEC who underwent a (68)Ga-DOTATOC PET/CT between November 2012 and May 2014, were retrospectively included. By real-time polymerase chain reaction, we quantitatively determined the gene expression of several genes and compared with (68)Ga-DOTATOC PET uptake. By immunohistochemistry we qualitatively studied the expression of assorted proteins in NEC. The median age at diagnosis was 68 years (range 41-84) years. All patients had WHO performance status 0-1. Median Ki67 index was 50% (range 20-100%). Gene expression of somatostatin receptor subtype (SSTR) 2 and Ki67 were both positively correlated to the (68)Ga-DOTATOC uptake (r=0.89; p<0.0001 and r=0.5; p=0.021, respectively). Furthermore, SSTR2 and SSTR5 gene expression were strongly and positively correlated (r=0.57; p=0.006). This study as the first verifies a positive and close correlation of (68)Ga-DOTATOC uptake and gene expression of SSTR2 in NEC. SSTR2 gene expression has a stronger correlation to (68)Ga-DOTATOC uptake than SSTR5. In addition, the results indicate that the gene expression levels of SSTR2 and SSTR5 at large follow one another.

摘要

在神经内分泌癌(NEC)患者中,将生长抑素受体在蛋白质和基因表达水平上的表达与体内(68)Ga-DOTATOC PET/CT进行了比较。回顾性纳入了2012年11月至2014年5月期间接受(68)Ga-DOTATOC PET/CT检查且确诊为NEC的21例患者。通过实时聚合酶链反应,我们定量测定了几种基因的基因表达,并与(68)Ga-DOTATOC的摄取情况进行了比较。通过免疫组织化学,我们定性研究了NEC中各种蛋白质的表达。诊断时的中位年龄为68岁(范围41-84岁)。所有患者的世界卫生组织体能状态均为0-1级。Ki67指数中位数为50%(范围20-100%)。生长抑素受体亚型(SSTR)2的基因表达和Ki67均与(68)Ga-DOTATOC的摄取呈正相关(r分别为0.89;p<0.0001和r为0.5;p=0.021)。此外,SSTR2和SSTR5基因表达呈强正相关(r=0.57;p=0.006)。本研究首次证实了NEC中(68)Ga-DOTATOC摄取与SSTR2基因表达呈正相关且密切相关。SSTR2基因表达与(68)Ga-DOTATOC摄取的相关性比SSTR5更强。此外,结果表明SSTR2和SSTR5的基因表达水平在很大程度上相互跟随。